Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,596
  • Shares Outstanding, K 5,552
  • Annual Sales, $ 11,200 K
  • Annual Income, $ 10 K
  • EBIT $ -6 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.03
  • Price/Sales 2.11
  • Price/Cash Flow N/A
  • Price/Book 1.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.60
  • Number of Estimates 1
  • High Estimate -0.60
  • Low Estimate -0.60
  • Prior Year 0.33
  • Growth Rate Est. (year over year) -281.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +42.95%
on 12/04/25
4.35 -2.07%
on 12/19/25
+1.10 (+34.81%)
since 11/21/25
3-Month
2.52 +69.05%
on 11/04/25
4.35 -2.07%
on 12/19/25
+1.40 (+48.95%)
since 09/22/25
52-Week
2.52 +69.05%
on 11/04/25
5.50 -22.55%
on 01/07/25
-0.61 (-12.53%)
since 12/20/24

Most Recent Stories

More News
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

SALT LAKE CITY , Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 4.26 (+0.24%)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 4.26 (+0.24%)
Lipocine: Q3 Earnings Snapshot

Lipocine: Q3 Earnings Snapshot

LPCN : 4.26 (+0.24%)
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

SALT LAKE CITY , Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 4.26 (+0.24%)
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

SALT LAKE CITY , Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 4.26 (+0.24%)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

One-Third of Patients Randomized; Topline Results Expected in 2Q 2026

LPCN : 4.26 (+0.24%)
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

SALT LAKE CITY , Sept. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...

LPCN : 4.26 (+0.24%)
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

SALT LAKE CITY , Aug. 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...

LPCN : 4.26 (+0.24%)
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

SALT LAKE CITY , Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with...

LPCN : 4.26 (+0.24%)
Lipocine: Q2 Earnings Snapshot

Lipocine: Q2 Earnings Snapshot

LPCN : 4.26 (+0.24%)

Business Summary

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its...

See More

Key Turning Points

3rd Resistance Point 4.60
2nd Resistance Point 4.45
1st Resistance Point 4.36
Last Price 4.26
1st Support Level 4.12
2nd Support Level 3.97
3rd Support Level 3.88

See More

52-Week High 5.50
Fibonacci 61.8% 4.36
Last Price 4.26
Fibonacci 50% 4.01
Fibonacci 38.2% 3.66
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar